Terms: = Germ cell tumor AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Prognosis
77 results:
1. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
Zhang W; Wang S
Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
[TBL] [Abstract] [Full Text] [Related]
2. Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
Kim HE; Kim J; Park HK; Lee JB; Yun SJ
Melanoma Res; 2024 Feb; 34(1):38-43. PubMed ID: 37924528
[TBL] [Abstract] [Full Text] [Related]
3. Anti-Vascular Endothelial Growth Factor Therapy Abolishes Glioma-Associated Endothelial cell-Induced tumor Invasion.
Tang F; Li FP; Huang XT; Wang GH; Wang ZF; Li ZQ
J Mol Neurosci; 2023 Mar; 73(2-3):104-116. PubMed ID: 36653624
[TBL] [Abstract] [Full Text] [Related]
4. Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective.
Khan M; Ai M; Du K; Song J; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Zhang J; Tian Y; Yuan Y
Front Immunol; 2022; 13():1062225. PubMed ID: 36605187
[TBL] [Abstract] [Full Text] [Related]
5. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract] [Full Text] [Related]
6. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
[TBL] [Abstract] [Full Text] [Related]
7. Dynamic analysis of immune status in patients with intracranial germ cell tumor and establishment of an immune risk prognostic model.
Wang H; Huang H; Lin X; Chi P; Chen H; Chen J; Mou Y; Chen Z; Yang Q; Guo C
Front Immunol; 2022; 13():1010146. PubMed ID: 36304453
[TBL] [Abstract] [Full Text] [Related]
8. tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
Noyes D; Bag A; Oseni S; Semidey-Hurtado J; Cen L; Sarnaik AA; Sondak VK; Adeegbe D
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618289
[TBL] [Abstract] [Full Text] [Related]
9. A Transcriptional Signature of PDGF-DD Activated Natural Killer cells Predicts More Favorable prognosis in Low-Grade Glioma.
Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
Front Immunol; 2021; 12():668391. PubMed ID: 34539622
[TBL] [Abstract] [Full Text] [Related]
10. Targeting the il-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
Moschos SJ; Eroglu Z; Khushalani NI; Kendra KL; Ansstas G; In GK; Wang P; Liu G; Collichio FA; Googe PB; Carson CC; McKinnon K; Wang HH; Nikolaishvilli-Feinberg N; Ivanova A; Arrowood CC; Garrett-Mead N; Conway KC; Edmiston SN; Ollila DW; Serody JS; Thomas NE; Ivy SP; Agrawal L; Dees EC; Abbruzzese JL
Melanoma Res; 2021 Apr; 31(2):162-172. PubMed ID: 33661190
[TBL] [Abstract] [Full Text] [Related]
11. Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms.
Herman Mahečić D; Cigrovski Berković M; Zjačić-Rotkvić V; Čačev T; Kapitanović S; Ulamec M
Bosn J Basic Med Sci; 2020 Nov; 20(4):445-450. PubMed ID: 32156252
[TBL] [Abstract] [Full Text] [Related]
12. The Synergistic Use of IL-15 and il-21 for the Generation of NK cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract] [Full Text] [Related]
13. An autophagy-related long non-coding RNA signature for glioma.
Luan F; Chen W; Chen M; Yan J; Chen H; Yu H; Liu T; Mo L
FEBS Open Bio; 2019 Apr; 9(4):653-667. PubMed ID: 30984540
[TBL] [Abstract] [Full Text] [Related]
14. PCC0208018 exerts antitumor effects by activating effector T cells.
Ge M; Hu Z; Chen X; Du G; Wang H; Liu R; Ye L; Tian J
Int J Immunopathol Pharmacol; 2019; 33():2058738419843366. PubMed ID: 30968715
[TBL] [Abstract] [Full Text] [Related]
15. Immunotherapy in melanoma.
Feld E; Mitchell TC
Immunotherapy; 2018 Aug; 10(11):987-998. PubMed ID: 30149766
[TBL] [Abstract] [Full Text] [Related]
16. The effects of interleukin 2 and rAd-p53 as a treatment for glioblastoma.
Qiao HB; Li J; Lv LJ; Nie BJ; Lu P; Xue F; Zhang ZM
Mol Med Rep; 2018 Mar; 17(3):4853-4859. PubMed ID: 29328445
[TBL] [Abstract] [Full Text] [Related]
17. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.
Liu Z; Poiret T; Persson O; Meng Q; Rane L; Bartek J; Karbach J; Altmannsberger HM; Illies C; Luo X; Harvey-Peredo I; Jäger E; Dodoo E; Maeurer M
Cancer Immunol Immunother; 2018 Feb; 67(2):237-246. PubMed ID: 29058035
[TBL] [Abstract] [Full Text] [Related]
18. Killing effect of methionine enkephalin on melanoma in vivo and in vitro.
Wang DM; Jiao X; Plotnikoff NP; Griffin N; Qi RQ; Gao XH; Shan FP
Oncol Rep; 2017 Oct; 38(4):2132-2140. PubMed ID: 28849104
[TBL] [Abstract] [Full Text] [Related]
19. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
[TBL] [Abstract] [Full Text] [Related]
20. Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.
Szychot E; Peregud-Pogorzelski J; Wawryków P; Brodkiewicz A
Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):1001-1004. PubMed ID: 27708204
[TBL] [Abstract] [Full Text] [Related]
[Next]
